Background: Vasomotor rhinitis (VMR) is a hypersensitivity syndrome with heightened reactivity to environmental triggers.
Methods: Twenty-two patients with severe VMR were treated nasally with either normal saline or 0.6% olopatadine and challenged nasally with a hyperosmolar mannitol solution.
Results: Treatment with 0.6% olopatadine resulted in an improvement in instantaneous nasal symptom scores at 5 and 30 minutes (p < 0.01) compared with baseline and at 30 minutes after hyperosmolar challenge compared with saline-pretreated individuals (p < 0.01). There was also an improvement in nasal peak inspiratory flow rate at 30 minutes after hyperosmolar challenge compared with saline-pretreated individuals (p < 0.01).
Conclusion: In this patient population 0.6% olopatadine appears to be efficacious in symptom reduction in VMR and protects from hyperosmolar challenge.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2500/ajra.2011.25.3620 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regulatory Perspective Reverse Engineering Analysis of the Mast Cell Stabilizer and the Histamine Receptor Antagonist (Olopatadine HCl): Instrumental and Classical Methods for Multiple Formulations.
ACS Omega
June 2023
School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus, University of KwaZulu-Natal, P Bag X 54001, Durban 4000, South Africa.
Article Synopsis
- - The study focuses on evaluating the qualitative and quantitative aspects of olopatadine HCl nasal spray and ophthalmic solutions by using various techniques to match generic formulations with reference drugs, avoiding the need for clinical trials.
- - A highly sensitive HPLC method was utilized to accurately quantify ingredients such as EDTA, BKC, NaCl, and DSP in both formulations, demonstrating that they have similar components.
- - The methods used for analysis showed high accuracy and precision, with correlation coefficients over 0.999 and recovery rates ranging from 99.1% to 100.8%, confirming their reliability in identifying the components in the formulations.
Assessment of the efficacy of olopatadine 0.1% in the treatment of vernal keratoconjunctivitis in terms of clinical improvement based on total ocular symptom score and ocular surface disease index.
Indian J Ophthalmol
May 2023
Command Hospital Airforce, Bengaluru, Karnataka, India.
Purpose: The main objective of this study is to explore the efficacy of olopatadine 0.1% treatment in the resolution of symptoms of vernal keratoconjunctivitis (VKC) among the Indian population.
Methods: This single-center, prospective cohort study involved 234 patients with VKC.
The rising cost of rhinologic medications.
Ann Allergy Asthma Immunol
September 2023
Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, California. Electronic address:
Background: The high prescription drug cost in the United States may negatively affect patient prognosis and treatment compliance.
Objective: To fill the knowledge gap and inform clinicians regarding rhinology medications price changes by evaluating trends in price changes of highly used nasal sprays and allergy medications.
Methods: The 2014-2020 Medicaid National Average Drug Acquisition Cost database was queried for drug pricing information for the following classes of medications: intranasal corticosteroids, oral antihistamines, antileukotrienes, intranasal antihistamines, and intranasal anticholinergics.
Efficacy and safety of GSP301 nasal spray in children aged 6 to 11 years with seasonal allergic rhinitis.
Ann Allergy Asthma Immunol
November 2022
Glenmark Pharmaceuticals Europe Ltd, Watford, United Kingdom.
Article Synopsis
- GSP301 nasal spray combines the antihistamine olopatadine and corticosteroid mometasone furoate to treat seasonal allergic rhinitis in pediatric patients aged 6-12 years.
- In a double-blind study with 446 participants, GSP301 significantly improved nasal symptoms compared to placebo, particularly in overall nasal symptom scores and quality of life measures.
- While both groups experienced treatment-emergent adverse events at similar rates, only one serious adverse event occurred in the placebo group, indicating GSP301's safety profile is comparable to that of a placebo.
Pupil Diameter, Corneal Thickness, and Anterior Chamber Alterations Following Topical Olopatadine Hydrochloride 0.1%: A Single-Masked Randomized Controlled Clinical Study.
J Ocul Pharmacol Ther
September 2020
Department of Ophthalmology, Ankara City Hospital, Ankara, Turkey.
Olopatadine hydrochloride 0.1% is one of the known primary topical treatments in ocular allergy. Although olopatadine is a worldwide used medication, the changes in pupil diameter, cornea, and anterior chamber associated with its use have not been studied in detail.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!